oxociprofloxacin: structure given in first source; ciprofloxacin metabolite [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 128242 |
| CHEBI ID | 192773 |
| SCHEMBL ID | 9686037 |
| MeSH ID | M0166960 |
| Synonym |
|---|
| oxociprofloxacin |
| 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(3-oxo-1-piperazinyl)-3-quinolinecarboxylic acid |
| CHEBI:192773 |
| 103237-52-1 |
| 1-cyclopropyl-6-fluoro-4-oxo-7-(3-oxopiperazin-1-yl)quinoline-3-carboxylic acid |
| FT-0673360 |
| 3-quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(3-oxo-1-piperazinyl)- |
| bay-q 3542 |
| 4-oxociprofloxacin |
| unii-y901rq8cdm |
| y901rq8cdm , |
| 3'-oxociprofloxacin |
| 3-quinolinecarboxylicacid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(3-oxo-1-piperazinyl)- |
| MYYZZOHRULFPOQ-UHFFFAOYSA-N |
| SCHEMBL9686037 |
| DTXSID80145706 |
| AKOS030241012 |
| Q27294389 |
| 1-cyclopropyl-6-fluoro-4-oxo-7-(3-oxopiperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The pharmacokinetic parameters for ciprofloxacin were not significantly altered in cirrhotic patients." | ( The effect of cirrhosis on the steady-state pharmacokinetics of oral ciprofloxacin. Frost, RW; Krol, G; Lasseter, KC; Lettieri, JT; Shamblen, EC, 1989) | 0.28 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Therefore it appears from this study that no dosage adjustment is required in patients with hepatic cirrhosis." | ( The effect of cirrhosis on the steady-state pharmacokinetics of oral ciprofloxacin. Frost, RW; Krol, G; Lasseter, KC; Lettieri, JT; Shamblen, EC, 1989) | 0.28 |
| Role | Description |
|---|---|
| drug metabolite | null |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| N-arylpiperazine | |
| piperazinone | |
| cyclopropanes | Cyclopropane and its derivatives formed by substitution. |
| quinolinemonocarboxylic acid | Any aromatic carboxylic acid that contains a quinoline moiety that is substituted by one carboxy substituent. |
| quinolone | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Pathway | Proteins | Compounds |
|---|---|---|
| Drug ADME | 63 | 87 |
| Ciprofloxacin ADME | 5 | 13 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (60.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (20.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||